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Introduction
Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in men in the US (1). Prostate cancer results from the accumulation of mutations that affect regulatory pathways controlling cell growth, differentiation, and death. ELL-associated factor 2, also known as androgen upregulated 19, (EAF2/U19) is a putative transcription factor and was discovered to be a protein up-regulated by the androgen receptor in the normal prostate. Over-expression of EAF2 induces apoptosis in prostate cancer cell lines while EAF2 is down-regulated in the majority of human prostate cancer specimens (2) . Furthermore, loss of EAF2 in mice results in prostatic intraepithelial neoplasia, the putative precursor of prostate cancer (3) . ELLassociated factor 1 (EAF1) is the only homolog of EAF2 in mammalians and is believed to play a role in leukemia (4, 5) . Studying how the EAF family proteins are regulated and which proteins EAF2 interacts with and whether that interaction plays a role in prostate cancer development and progression may provide methods to treat prostate cancer.
The initial project was based on preliminary data which showed the presence of modified EAF1 and EAF2, which are about two times heavier than the unmodified EAF1 and EAF2. Furthermore, preliminary data showed that the addition of MG132 increases EAF1 and EAF2 protein levels and causes EAF2 to localize to the nucleus. An in silico analysis of EAF1 and EAF2 amino acid sequences using SUMOplot (6) predicted 2 potential sumoylation sites in EAF1, K54 and K174, as well as two potential sumoylation sites in EAF2, K18 and K164. Increased sumoylation caused a drop in EAF1 levels and a shift in EAF1 localization. The three specific aims for the project were as follows: specific aim 1 was to determine the nature of the modification of EAF1 and EAF2, specific aim 2 was to determine if the modification affects EAF1 and EAF2 function, and specific aim 3 was to understand the roles of sumoylation and protein degradation in EAF1 and EAF2 localization. However, due to the difficulties of providing conclusive evidence that the observed EAF1 and EAF2 modifications were a covalent dimerization, a new project was devised.
The preliminary evidence for the new project was an RNAi phenotypic enhancer screen using the C. elegans in which the homolog of EAF2, eaf-1, had been knocked out. Loss of eaf-1 results in reduced fertility and a positive hit would be the loss of a second gene that renders the C. elegans sterile. There was a brief focus on two of the positive hits from the screen, hmg-1.2, the C. elegans homolog to HMGB1 and pha-4, the C. elegans homolog to FOXA1. HMGB1 is high mobility group box 1 protein, a non-histone non-specific DNA binding protein in the nucleus, a mediator of autophagy in the cytoplasm, and a cytokine when it is extracellular (7) . Furthermore, high levels of HMGB1 are associated with worse outcomes in prostate cancer (8) . FOXA1 is forkhead box protein A1 and it is a pioneer factor for the androgen receptor (AR). FOXA1 binds to chromatin, rearranges the nucleosomes to make open chromatin, and then AR binds to FOXA1 to begin gene transcription (9, 10) . FOXA1 is required for the development of ductal epithelial cells in the prostate and high levels of FOXA1 in advanced prostate cancer is indicative of a poor patient outcome (11, 12) . There was also preliminary evidence that FOXA1 and EAF2 associate while HMGB1 and EAF2 did not associate. EAF2 was observed to alter HMGB1 localization, but this was only in ~30% of co-transfected cells. Therefore the decision was made to focus on the interaction of FOXA1 and EAF2. The three specific aims for the new project were as follows: specific aim 1 will determine how FOXA1 interacts with EAF2 and specific aim 2 will determine the effect of EAF2 on FOXA1-mediated transcription and on FOXA1-mediated cell growth and survival. The new set of specific aims were completed and turned into a Ph.D. dissertation.
Body

EAF1 and EAF2 form homodimers when over-expressed
In 2011, when the original grant was submitted, it was thought that the observed modification ( Figure 1 ) was likely due to either polyubiquitination or polysumoylation. Due to concerns over the size of the modification, a co-immunoprecipitation was performed to eliminate the possibility of a dimerization. As seen in Figure 2 , the co-immunoprecipitation showed that the post-translational modification was due to covalent dimerization. At the time it was shown that the modification was due to dimerization, EAF1 mutants were generated that lack the potential sumoylation sites by mutating the lysine residues (K) that were predicted to be sumoylated to arginine residues (R). A co-immunoprecipitation was performed to determine if the EAF1 K54R or the EAF1 K174R mutant showed altered dimerization. As can be seen in Figure 3 , the mutants underwent dimerization in a manner similar to the wild-type protein, but the protein levels of the mutated EAF1 were reduced.
Loss of hmg-1.2 or pha-4 in eaf-1 knockout C. elegans results in sterility Based on this evidence, the decision was made to switch projects. At the same time, a screen was performed in C. elegans to find genes that may interact with EAF2. In C. elegans, there is a homolog to EAF1 and EAF2, eaf-1. When eaf-1 is knocked out in C. elegans, reduced fertility, shortened body length, and increased death is observed. The screen was designed to find phenotypic enhancers, mutations that make a phenotype worse (13, 14) . The read-out for the screen was reduced fertility, with a positive RNAi resulting in severely reduced fertility or sterility. Two of the hits from the screen, which used a library of nuclear factors, were RNAi knockdowns of hmg-1.2, the C. elegans homolog of HMGB1, and pha-4, the C. elegans homolog of FOXA1. Figure 4 shows that loss of either hmg-1.2 or pha-4 in eaf-1 knockout C. elegans results in sterility. After examining the resulting offspring ( Figure 5 ), it was noted that the eaf-1 knockout C. elegans treated with hmg-1.2 RNAi were prone to vulval extrusion, where the guts of the C. elegans come out through the vulva due to cuticle abnormalities, the eaf-1 knockout C. elegans treated with pha-4 RNAi suffered egg degeneration, and there were no notable problems in the other C. elegans samples.
In addition to the results of the C. elegans screen, hmg-1.2 and pha-4 had mammalian homologs that were known to play a role in prostate cancer. One of the mammalian homologs of hmg-1.2 is HMGB1, which is known to play a role in autophagy and it has been observed that high levels of HMGB1 indicates a poor outcome in prostate cancer (7, 8) . One of the mammalian homologs of pha-4 is FOXA1, which is a pioneer factor for the androgen receptor, and it has been observed that FOXA1 levels are elevated in castration-resistant prostate cancer and high FOXA1 protein levels indicate a poor outcome in prostate cancer (12, 15) . Several experiments were performed in order to determine whether to focus on HMGB1 or FOXA1. Cotransfections of hmg-1.2 and eaf-1 and HMGB1 and EAF2 were performed in 293 cells ( Figure 6 ). The cotransfections showed that the presence of EAF2 family proteins caused HMGB1 family proteins to translocate to the cytoplasm. The HMGB1 family proteins are DNA-binding proteins in the nucleus, mediators of autophagy in the cytoplasm, and cytokines when extra-cellular (7) . Co-transfections of FOXA1 and EAF2 showed that EAF2 associated with FOXA1 ( Figure 7 ) and both EAF2 and FOXA1 protein levels were reduced when co-transfected compared to transfection with the empty vector ( Figure 8 ). Based on the results and the literature on FOXA1, the decision was made to focus on the interaction of FOXA1 and EAF2.
FOXA1 and EAF2 interaction hypothesis
The hypothesis for the new project was based on the known roles of FOXA1 and EAF2 in prostate cancer.
FOXA1 is known to promote tumor progression in metastatic and castration-resistant prostate cancer, while EAF2 is known to be a tumor suppressor. This suggested the model that when EAF2 levels are reduced during prostate cancer, FOXA1 levels rise, shifting the cell into a more oncogenic state ( Figure 9 ). The hypothesis was that EAF2 associates with FOXA1 to modulate AR transactivation.
FOXA1 associates with the N-terminus and the C-terminus of EAF2
The next set of experiment was performed in order to determine which regions of EAF2 are required for the association of FOXA1 and EAF2. As seen in Figures 10 and Figure 11 , FOXA1 associated with both the Nterminus and C-terminus of EAF2. Both the N-terminus and C-terminus of EAF2 are involved in transcription elongation (5, 16) .
Over-expression of FOXA1 and EAF2 reduce the protein levels of both proteins; FOXA1 protein levels increase and PSA protein and mRNA levels decrease when EAF2 is reduced
One of the next questions was whether the observed reduction of FOXA1 and EAF2 protein levels when coexpressed occurred at the endogenous level. FOXA1 protein levels were measured in the anterior prostates of EAF2 knockout mice. As seen in Figure 12 , FOXA1 protein levels were elevated in EAF2 knockout mice.
When EAF2 is knocked down in LNCaP cells, FOXA1 protein levels increase and PSA protein levels decrease, which suggests that loss of EAF2 alters FOXA1-mediated AR signaling ( Figure 13 ). In addition, PSA mRNA levels are decreased in EAF2 knockdown LNCaP cells ( Figure 14 ).
Over-expression of FOXA1 inhibits PSA promoter activity
The next set of experiments was based on the discovery that loss of EAF2 reduced PSA mRNA levels. First, a luciferase assay was performed to measure PSA promoter activity when FOXA1 is over-expressed in C4-2 cells. The luciferase assay showed that FOXA1 reduced PSA promoter activity in a dose-dependent manner in the presence and absence of supplemental androgen, which matched previous reports ( Figure 15 ) (17). This supported the earlier observed result that loss of EAF2 increased FOXA1 and decreased PSA.
Over-expression of FOXA1 and EAF2 produces an intermediate cell survival and proliferation phenotype
The final set of experiments that were performed was colony formation assays to determine if co-transfection of 
Results Conclusion
The plan for the FOXA1 and EAF2 project was to spend months 1-14 determining how 
Key Research Accomplishments
 EAF1 and EAF2 each form covalent dimers.
 The C. elegans homologs of HMGB1 and EAF2, hmg-1.2and eaf-1, interact and loss of hmg-1.2 in eaf-1 knockout C. elegans results in sterility. 
Conclusion
The project was designed to investigate how the tumor suppressor EAF2 is regulated in the normal prostate and dysregulated during prostate cancer and to support the doctoral training of the primary investigator. Initially, the focus of the research was to determine the role a protein modification of EAF2 played in the regulation of EAF2, but the focus shifted to investigating a potential interaction between EAF2 and FOXA1 and the role the interaction played regulating EAF2 and FOXA1, FOXA1-mediated androgen receptor signaling, and cell growth and survival. This research did show that the interaction between FOXA1 and EAF2 may represent a feedback loop that modulates androgen receptor signaling ( Figure 17 ) and may play a role in regulating cell growth and survival. The primary investigator is also working on submitting a paper based on this research. In addition, the primary investigator has successfully submitted a dissertation based on the research this grant supported and will officially graduate with a PhD in April 2014. The project has successfully found an interesting mechanism by which EAF2 can modulate androgen receptor signaling and further elucidates the effects of EAF2 down-regulation in prostate cancer. 
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